Get the Stockscreener App
2.23
0.90%
0.02
Lexaria Bioscience Corp stock is traded at $2.23, with a volume of 91,558.
It is up +0.90% in the last 24 hours and up +1.36% over the past month.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
See More
Previous Close:
$2.21
Open:
$2.22
24h Volume:
91,558
Relative Volume:
0.63
Market Cap:
$38.92M
Revenue:
$411.00K
Net Income/Loss:
$-4.85M
P/E Ratio:
-1.9735
EPS:
-1.13
Net Cash Flow:
$-4.88M
1W Performance:
-0.45%
1M Performance:
+1.36%
6M Performance:
-22.57%
1Y Performance:
+71.54%
1-Day Range:
$2.15
$2.24
1-Week Range:
$2.00
$2.31
52-Week Range:
$1.20
$6.85
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Name
Lexaria Bioscience Corp
Sector
Industry
Phone
250-765-6424
Address
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
2.23 | 38.92M | 411.00K | -4.85M | -4.88M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lexaria Bioscience Corp Stock (LEXX) Latest News
Lexaria's Registered GLP-1 Study #4 Begins Dosing - Yahoo Finance
Lexaria Bioscience finalizes clinical study agreement By Investing.com - Investing.com South Africa
Lexaria forms scientific advisory board to enhance drug delivery tech - Investing.com
Lexaria Bioscience Forms Elite Scientific Advisory Board with Harvard Medical School Expert - StockTitan
Lexaria Bioscience Taps Harvard Medical Expert to Accelerate GLP-1 & Hypertension Drug Development - StockTitan
Lexaria Bioscience engages CRO for human pilot study of DehydraTEHC-liraglutide - Yahoo Finance
Lexaria's Oral GLP-1 Drug Shows Promise: Plans First Human Trial After Beating Rybelsus in Animal Study - StockTitan
Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5 - Yahoo Finance
LEXX (Lexaria Bioscience) Enterprise Value : $38.78 Mil (As of Dec. 06, 2024) - GuruFocus.com
LEXX: Phase I Start Imminent - Yahoo Finance
Q1 EPS Forecast for Lexaria Bioscience Decreased by Analyst - Defense World
LEXX (Lexaria Bioscience) Market Cap : $47.13 Mil (As of Dec. 03, 2024) - GuruFocus.com
Insider Buying: Richard Christopher Acquires 50,000 Shares of Le - GuruFocus.com
Lexaria Bioscience CEO buys $118,391 in shares By Investing.com - Investing.com Nigeria
Lexaria Bioscience CEO buys $118,391 in shares - Investing.com
Lexaria Bioscience (NASDAQ:LEXX) Receives Buy Rating from HC Wainwright - Defense World
Lexaria Bioscience keeps stock target with Buy rating on financial results - Investing.com
LEXXW (Lexaria Bioscience) 3-Year Revenue Growth Rate : -39.20% (As of Aug. 2024) - GuruFocus.com
BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, & Surge Battery Metals - Markets Insider
Lexaria's DehydraTECH Breakthrough: Fox Business to Spotlight Drug Delivery Innovation | LEXX Stock News - StockTitan
Lexaria Bioscience Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
SEC Form DEF 14A filed by Lexaria Bioscience Corp. - Quantisnow
Form DEF 14A Lexaria Bioscience Corp. For: Jan 14 - StreetInsider.com
Lexaria Bioscience Corp. (LEXX) reports earnings - Quartz
Lexaria: GLP-1 Drugs Expand Beyond Weight Loss Into Major Disease Treatments | LEXXW Stock News - StockTitan
Lexaria: GLP-1 Drugs Expand Beyond Weight Loss Into Major Disease Treatments - StockTitan
Lexaria Bioscience holds buy rating, steady stock target on positive study results - Investing.com Canada
Lexaria Completes Human Trial of Oral Tirzepatide Alternative to $15B Mounjaro Drug | LEXXW Stock News - StockTitan
Lexaria Completes Human Trial of Oral Tirzepatide Alternative to $15B Mounjaro Drug - StockTitan
Lexaria Bioscience’s DehydraTECH Outshines in Diabetes Study - TipRanks
ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study - JCN Newswire
Lexaria's DehydraTECH Outperforms Rybelsus in Diabetes Study with 11.5% Better Weight Loss - StockTitan
LEXXWLexaria Bioscience Corp. Warrant Latest Stock News & Market Updates - StockTitan
Invenomic Capital Management LP Adjusts Stake in Lexaria Bioscie - GuruFocus.com
Lexaria commences unique drug distribution study - Investing.com
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study - WICZ
Lexaria Signs Contract for New DehydraTECH GLP-1 Biodistribution Study - ACN Newswire
Lexaria Launches Groundbreaking Semaglutide Study vs. Rybelsus Formulation - StockTitan
LEXXLexaria Bioscience Corp. Latest Stock News & Market Updates - StockTitan
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss - Yahoo Finance
Lexaria Bioscience Corp. (LEXX) Quarterly 10-Q Report - Quartzy
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments - Yahoo Finance
Lexaria Positions DehydraTECH Platform in Booming $471B GLP-1 Drug Market - StockTitan
Lexaria reports promising blood sugar control in animal study - Investing.com India
Lexaria reports promising blood sugar control in animal study By Investing.com - Investing.com Australia
Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study - StockTitan
Lexaria reports advances in weight loss drug study - Investing.com India
Lexaria reports advances in weight loss drug study By Investing.com - Investing.com UK
Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study - StockTitan
Lexaria Bioscience : Corporate Presentation - Marketscreener.com
Lexaria Bioscience Corp. sets date for combined annual and special meeting - Investing.com India
Lexaria Bioscience Corp Stock (LEXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexaria Bioscience Corp Stock (LEXX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CHRISTOPHER RICHARD | Chief Executive Officer |
Dec 02 '24 |
Buy |
2.24 |
22,828 |
51,217 |
22,828 |
| TURKEL CATHERINE C. | Director |
Aug 12 '24 |
Buy |
3.13 |
1,600 |
5,008 |
3,100 |
| Carle Vanessa | Secretary |
Jul 31 '24 |
Sale |
4.00 |
2,567 |
10,268 |
0 |
| Carle Vanessa | Secretary |
May 14 '24 |
Option Exercise |
1.15 |
2,500 |
2,875 |
2,567 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):